White & Case LLP has advised ICON plc. Latham & Watkins LLP has advised the initial purchasers. ICON plc, a world-leading clinical research organization headquartered in...
ICON Completes US$2.15 Billion Senior Unsecured Notes Offering
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
Serapha Bio and Boundless Bio Announce Merger and $230 Million Private Placement
Gibson Dunn has advised Serapha Bio, Inc. Latham & Watkins has advised Boundless Bio, Inc. Serapha Bio, Inc., a privately held biotechnology company, and Boundless Bio,...
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering
Latham & Watkins LLP has advised Mineralys Therapeutics. Cleary Gottlieb has represented the underwriters, including BofA Securities Inc., Goldman Sachs & Co. LLC, and Evercore Group...
Corvus Pharmaceuticals Completes US$201 Million Upsized Public Offering
Latham & Watkins LLP has advised Corvus Pharmaceuticals. Paul Hastings LLP has advised Jefferies and Goldman Sachs & Co. LLC. Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) has...
CD&R’s $10.3 Billion Acquisition of Sealed Air Corporation
Latham & Watkins LLP has advised Sealed Air. Kirkland & Ellis LLP and Debevoise & Plimpton LLP have advised CD&R. Sealed Air Corporation, a global provider...
Arcus Biosciences Completes $287.5 Million Common Stock Offering
Latham & Watkins has advised Arcus Biosciences. Gunderson Dettmer has advised the underwriters. Arcus Biosciences, a clinical-stage, global biopharmaceutical company listed on the NYSE under the...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
Cal-Maine Foods’ $276 Million Common Stock Offering and $50 Million Share Repurchase
Sidley Austin represented Cal-Maine Foods, Inc., while Latham & Watkins represented the underwriter in the offering and Whalen LLP represented the Selling Stockholders. Cal-Maine Foods, Inc....
Boston Scientific’s Acquisition of SoniVie Ltd.
Latham & Watkins advised Boston Scientific, while K&L Gates advised SoniVie Ltd. on the transaction. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Carlyle and SK Capital’s Acquisition of bluebird bio
Wachtell, Lipton, Rosen & Katz, Kirkland & Ellis, and Orrick, Herrington & Sutcliffe are serving as legal advisors to Carlyle and SK Capital, while Latham &...